Acadia announced that the Food and Drug Administration (FDA) has approved a new capsule formulation and a new tablet strength for Nuplazid (pimavanserin) for use in patients with hallucinations and delusions associated with Parkinson’s disease psychosis.

The new 34mg capsule formulation will help reduce pill burden and allow patients to take the recommended once-daily dose as a single capsule versus two 17mg tablets. Also, the new 10mg strength tablet offers a lower dosage strength for patients who are taking concomitant strong CYP3A4 inhibitors, which can potentiate pimavanserin. 

Nuplazid, a non-dopaminergic, selective serotonin inverse agonist, targets 5-HT2A receptors that are thought to be involved in Parkinson’s disease psychosis. Its effect may be mediated through a combination of inverse agonist and antagonist activity at serotonin 5-HT2A receptors and to a lesser extent at serotonin 5-HT2C receptors. 

Related Articles

Nuplazid is currently available as 17mg strength tablets in 60-count bottles. The 34mg capsules and 10mg tablets are anticipated to launch by mid-August 2018. 

For more information call (858) 558-2871 or visit